Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults
NCT03618381Phase 1Active, not recruiting
- Sponsor
- Seattle Children's
- Start
- Jun 2019
- Primary completion
- Jun 2040
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of EGFR806 CAR T cells in solid tumor (2 arms), sponsored by Seattle Children's. Primary endpoints: Maximum Tolerated Dose and Dose Limiting Toxicities at 28 days, Number of successfully manufactured CAR T cell products at 28 days and 1 more. Started Jun 2019; status: active, not recruiting.
02
Drugs
EGFR806 CAR T cells
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03618381.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03618381.